Private Equity Cannabis: Top Firms in 2026

Key Facts: Cannabis PE and VC at a Glance

• Approximately 98 cannabis PE and VC funds are tracked in industry fund databases as of January 2026, including 37 venture capital funds, 12 private equity funds, 4 hedge funds, 7 real estate funds, and 5 incubators.
• North American cannabis PE deal value reached $796 million in 2022, a 79% decline from approximately $3.82 billion in 2021, with only $18 million across 6 transactions recorded in Q1 2023.
• Entourage Effect Capital has deployed $200 million or more across 65+ portfolio companies. Merida Capital Holdings manages $200 million across five funds and 50+ portfolio companies.
• Viridian Capital Advisors has executed over $1 billion in cannabis and hemp capital raises spanning venture capital, private equity, growth equity, and debt instruments.
• New York is the single largest geographic hub with 42+ identified cannabis investors. California's Bay Area and Los Angeles corridor anchor seed and early-stage venture activity.
• Cannabis remains a Schedule I controlled substance at the federal level, restricting institutional capital access, standard banking relationships, and interstate commerce. This federal classification is the primary structural drag on deal activity since 2022.
• Q1 2023 recorded only six cannabis PE transactions totaling $18 million, the lowest quarterly figure in four years. Stalled federal legislation drove the deal-activity trough.

The Cannabis Investment Landscape

Cannabis private equity investing spans a broad spectrum, from seed-stage venture funds backing compliance software startups to growth equity platforms deploying tens of millions into multi-state operators. The sector divides along one structural line: plant-touching businesses (cultivation, extraction, dispensaries, consumer brands) versus ancillary companies (technology, compliance tools, staffing, packaging). That distinction shapes almost every investment mandate in the sector.

Federal Schedule I status subjects plant-touching operators to the 280E tax code and blocks standard banking access. It also limits the institutional LP universe to family offices, high-net-worth individuals, and specialized funds. This regulatory ceiling drove the market contraction that accelerated in 2022.

Deal value fell 79% in a single year as institutional capital retreated, pending federal reform. Passage of the SAFE Banking Act and potential rescheduling by the Department of Justice and the Department of Health and Human Services are the most-watched catalysts. As of year-end 2022, 22 US states had legalized adult-use cannabis and 39 had legalized medical use.

Germany and Luxembourg are advancing comprehensive legalization frameworks, opening new international investment corridors. Altitude Investment Management and Gotham Green Partners are already positioned to enter those markets. New York dominates domestic investor geography with 42+ identified cannabis capital providers, including Merida Capital Holdings, Altitude Investment Management, and Tuatara Capital.

California accounts for the majority of early-stage venture activity through Casa Verde Capital, HALLEY Venture Partners, Base Ventures, and Big Rock. Colorado, Illinois, and Texas round out the active state ecosystems. Green Lion Partners in Denver, Salveo Capital in Northbrook, and Entourage Effect Capital in Dallas represent those respective markets.

Firm Comparison at a Glance

The table below covers leading cannabis venture capital and private equity firms by strategy, sector strength, and notable attributes. AUM figures reflect publicly disclosed capital deployed or funds under management. Advisory-track figures for Viridian Capital Advisors reflect total capital raises executed on behalf of clients.

Only Entourage Effect Capital, Merida Capital Holdings, and Viridian Capital Advisors have disclosed capital figures. Most cannabis fund managers keep fund sizes private, typical given the limited LP universe and the sensitivity around institutional capital disclosure.

Top Picks by Investment Strategy

Largest Capital Deployed: Entourage Effect Capital holds this position by deal count and disclosed capital, with $200 million or more deployed across 65+ companies since 2014. No other cannabis-specific fund manager has publicly reported a larger portfolio by company count.

Best for Cultivation Technology: Merida Capital Holdings anchors its investment thesis in cannabis as an agricultural product and pharmaceutical feedstock. Its portfolio includes GrowGeneration (indoor cultivation supply, publicly traded) and New Frontier Data (cannabis market intelligence), both validating that thesis in commercial outcomes.

Top Ancillary/Tech Investor: Casa Verde Capital operates a strict no-plant-touching mandate, making it the natural target for founders building compliance software, point-of-sale systems, or cannabis supply chain technology. Its investments in Dutchie and Metrc are the most-cited proof points in the ancillary VC category.

Growth Capital Leader: Gotham Green Partners deploys growth equity from Series A through Series C across both public and private companies, with a global mandate extending beyond North America. This reach sets it apart from most cannabis PE investors, who operate domestically only.

Best for Cannabis Tech Startups: HALLEY Venture Partners applies an exclusive technology filter across its portfolio, backing springbig (loyalty and marketing software), Willow Industries (compliance solutions), and Front Range Biosciences (genetics research).

Strongest International Reach: Altitude Investment Management covers cannabis supply chain investments across North America and Europe, with portfolio companies including KannaSwiss and PathogenDX. It is one of the few cannabis-focused fund managers with a documented cross-border mandate.

Best Advisory for Capital Raises: Viridian Capital Advisors has executed over $1 billion in cannabis and hemp capital raises across every instrument type, operating as a registered broker-dealer through Bradley Woods & Co. (FINRA/SIPC member). Founders needing debt, bridge financing, or hybrid structures should engage advisory-layer firms before approaching direct equity investors.

Top Cannabis PE and VC Firms in Detail

Entourage Effect Capital

The broadest active portfolio in the cannabis PE sector belongs to Entourage Effect Capital. The firm has deployed $200 million or more across 65+ companies spanning the full value chain from cultivation to retail, a deal count unmatched for network density among cannabis-specific fund managers. Managing partners Matt Hawkins, Andy Sturner, and Dov Szapiro bring a combined 65+ years of venture experience across seed through growth stage.

Portfolio companies include Cookies (consumer brand), GrowFlow (cannabis software), and Cann (cannabis beverages). The fund covers both plant-touching and ancillary categories, giving it the widest investment mandate in the space.

Merida Capital Holdings

Merida's investment thesis is built on a specific claim: cannabis is simultaneously an agricultural product, a pharmaceutical ingredient, and a consumer good. Each vertical follows a distinct normalization timeline, and Merida's fund structure reflects that directly. Merida manages five funds totaling $200 million across 50+ portfolio companies, making it the most structured multi-vehicle cannabis PE manager operating today.

GrowGeneration (cannabis cultivation supply, publicly listed) and New Frontier Data (cannabis market intelligence) validate the agricultural thesis in commercial outcomes. Pharmaceutical-oriented cannabis businesses seeking growth stage capital from a GP with demonstrated exit experience should treat Merida as a primary target.

Gotham Green Partners

The most geographically ambitious firm in cannabis growth equity, Gotham Green Partners deploys capital from Series A through Series C across both publicly traded and private cannabis companies, with no restriction to North America. That public-plus-private mandate creates co-investment flexibility that most cannabis-only funds cannot match. Portfolio companies include Jane Technologies (cannabis e-commerce platform), Lift & Co. (Canadian cannabis events and data), and MedMen (multi-state dispensary operator).

Cannabis operators with cross-border ambitions, or those that have accessed public markets and need additional growth capital, will find Gotham Green among the most strategically aligned investors in the sector.

Casa Verde Capital

Casa Verde Capital has built its entire identity around a single constraint: no plant-touching investments. By refusing direct cannabis operator exposure, the fund sidesteps the 280E tax issue and federal banking restrictions that complicate plant-touching deals. Its portfolio includes Dutchie (cannabis point-of-sale and e-commerce platform) and Metrc (seed-to-sale compliance tracking used by state regulators).

Co-founded by Snoop Dogg, the fund leverages brand relationships and media reach that most cannabis VC competitors cannot replicate. Founders building SaaS, compliance, or supply chain software for the cannabis industry should prioritize Casa Verde Capital at the seed and early stage.

Altitude Investment Management

Altitude Investment Management is one of the few cannabis-focused venture capital firms with a documented commitment to both North American and European markets. Its principals come from distressed debt and leveraged credit backgrounds, giving the fund structural fluency in highly regulated industries that pure cannabis specialists often lack. Portfolio companies include PathogenDX (cannabis testing technology), Canndescent (premium cannabis brand), and KannaSwiss (European CBD).

The European angle is particularly relevant as Germany and Luxembourg advance legalization. Cannabis founders building supply chain technology or brands with cross-border aspirations can find in Altitude an investor with both the regulatory toolkit and international network to support that expansion.

Salveo Capital

Salveo Capital takes the broadest sector view of any cannabis fund in the Midwest, covering technology, biotech, medical applications, cultivation, retail, and ancillary services within a single mandate. Managing Partner Michael Gruber brings 25 years of early-stage investing in tech, finance, and agriculture. Managing Partner Jeffrey Howard adds 21 years of Wall Street experience, giving the fund a structurally sophisticated approach to deal terms.

Portfolio companies include Würk (cannabis workforce management and payroll) and Coda Signature (premium cannabis brand). Illinois-based cannabis operators and biotech founders seeking a fund manager with deep Midwest regulatory knowledge should evaluate Salveo Capital's Series A through Series C mandate.

HALLEY Venture Partners

Among cannabis venture capital firms, HALLEY Venture Partners applies the sharpest filter: technology only, at the highest scalability threshold. Led by Steve Schuman, who brings 17+ years of private and public equity experience across agriculture, technology, and manufacturing, the firm targets companies building defensible positions in the cannabis technology stack. Portfolio companies include springbig (cannabis loyalty and marketing software), Willow Industries (cannabis compliance and packaging), and Front Range Biosciences (plant genetics).

Cannabis tech founders with seed-stage companies targeting Series A or B should note that HALLEY's filter is strict. Businesses without a clear path to scale beyond cannabis into adjacent industries are unlikely to fit the mandate.

Green Lion Partners

Green Lion Partners serves a specific niche: early-stage ancillary cannabis companies in Colorado and adjacent Western markets, with emphasis on technology, consumer products, and business services. Co-founded by Jeffrey Zucker and Michael Bologna, the Denver-based firm has operated since 2015 with a consistent focus on professionalizing the cannabis industry. Its most prominent investment is Flowhub, a cannabis point-of-sale and compliance software company that became a category leader.

Green Lion Partners provides both capital and operational guidance. Founders at the early stage who need a hands-on partner with strong Colorado regulatory relationships should consider Green Lion a primary target.

Tuatara Capital

Tuatara Capital targets market-leading cannabis operators rather than early-stage ventures, applying a more traditional PE lens than most venture-oriented competitors. Based in New York with a Series A investment focus, the firm evaluates companies on their ability to sustain market leadership through operational discipline rather than growth-at-all-costs metrics. This positions Tuatara squarely in the segment where cannabis operators have moved past early-stage risk and need institutional-quality PE support to achieve defensible scale.

While Tuatara has not publicly disclosed its portfolio companies in detail, New York-based and multi-state cannabis operators that have demonstrated revenue and market position should consider Tuatara alongside Merida Capital as a growth PE option.

Viridian Capital Advisors

Viridian Capital Advisors operates in a different category from every other firm on this list: it is a capital placement advisory firm affiliated with a registered broker-dealer (Bradley Woods & Co., FINRA/SIPC member) rather than a direct investment fund. With over $1 billion in cannabis and hemp capital raises executed across venture capital, private equity, growth equity, bridge financing, and debt instruments, Viridian's deal intelligence spans the full instrument spectrum. The firm also publishes the Viridian Cannabis Deal Tracker, one of the most comprehensive databases of cannabis capital raises available.

Founders with capital needs that do not fit neatly into a single fund's mandate, or those requiring non-equity instruments, will find Viridian's multi-instrument capability and regulatory credibility valuable before approaching direct investors.

Investment Trends Shaping Cannabis Capital

Federal Reform as the Dominant Catalyst

Three regulatory variables dominate cannabis PE today: the SAFE Banking Act, the MORE Act (Marijuana Opportunity Reinvestment and Expungement Act), and the ongoing DOJ and HHS review of Schedule I cannabis classification. SAFE Banking Act passage alone would normalize operator banking access, reduce cost of capital, and unlock institutional LP appetite that has sat on the sidelines since 2021. Without federal action, dry powder in cannabis funds remains constrained to family offices and high-net-worth individuals rather than pension funds and endowments.

The Pivot to Ancillary and Non-Plant-Touching

Capital is flowing toward businesses that serve cannabis operators without handling the plant, specifically to avoid 280E tax exposure and federal banking restrictions. Cannabis point-of-sale platforms (Dutchie, Flowhub) and seed-to-sale compliance tracking (Metrc) attracted consistent investment through the 2022-2023 downturn. Cannabis workforce software like Würk maintained similar momentum, because revenue models in these categories are not directly tied to plant-touching regulatory risk.

This structural shift advantages fund managers like Casa Verde Capital and HALLEY Venture Partners, whose mandates were built for this constraint from the outset.

Price Compression and Consolidation Creating PE Opportunities

Adult-use cannabis prices have declined sharply since 2021, squeezing margins across cultivation and retail. That price compression is forcing weaker operators into distressed situations, creating buyout and restructuring opportunities for fund managers willing to navigate complex regulatory ownership transfers. WelCan Capital, Merida Capital Holdings, and Delta Emerald Ventures were the three most active PE investors in 2022, each closing three transactions. Selective buyers are finding value in a compressed market, even as aggregate deal volume falls.

International Expansion as a Growth Lever

Germany's comprehensive cannabis legalization, Luxembourg's advancing framework, and Canada's established market represent the clearest international investment corridors available to cannabis PE firms. Altitude Investment Management's existing European exposure and Gotham Green Partners' global mandate position both firms ahead of purely domestic competitors if European adult-use markets scale as anticipated. Green Acre Capital focuses specifically on the Canadian market, which remains the most developed regulatory model outside the United States.

Social Equity and ESG Capital Flows

New York's Cannabis Social Equity Investment Fund offers up to $200 million in total capacity, seeded by $50 million in state funds for Conditional Adult-Use Retail Dispensary (CAURD) licensees. California's Cannabis Equity Grants Program, Colorado's Cannabis Business Grant, and Massachusetts's Social Equity Program collectively channel capital toward founders from communities disproportionately affected by cannabis prohibition. The Arcview Group, one of the original cannabis angel investing networks, has social justice embedded in its investment thesis. These programs represent real capital sources that cannabis founders with qualifying backgrounds should evaluate alongside private VC and PE options.

How to Evaluate Cannabis PE Investors

The most important filter before any outreach is mandate alignment: confirm whether a fund can legally and operationally support your business type. A plant-touching cannabis operator approaching Casa Verde Capital or HALLEY Venture Partners will find those conversations unproductive, because both funds maintain strict ancillary-only policies. Matching plant-touching status to fund mandate before outreach saves both parties time and protects your deal timeline.

Stage and check size alignment is the second critical filter. Lower middle market cannabis VC typically writes checks between $100,000 and $5 million at seed and early stages. Established PE platforms like Entourage Effect Capital and Merida Capital Holdings have deployed $200 million or more and target larger, revenue-generating businesses.

Fund vintage and remaining uncommitted capital matter more in cannabis than in most sectors, because deal activity hit a four-year low in early 2023. Ask GPs directly about their current fund's deployment timeline and whether they are actively deploying or preparing a new vehicle. Use the Viridian Cannabis Deal Tracker and industry capital raise databases to verify which firms closed deals in the last 12 months. Stated mandates alone are insufficient; active deployment history is the more reliable signal.

Track record and exit history provide the clearest indication of fund quality. Merida Capital Holdings' GrowGeneration investment produced a publicly traded outcome. Casa Verde Capital's early backing of Dutchie produced a category-defining, exit-ready platform. For LPs evaluating the asset class, Poseidon Asset Management and Merida Capital Holdings offer the longest documented histories among structured fund vehicles in cannabis.

Institutional co-investors and participation in follow-on rounds are additional credibility signals worth verifying. Red flags include: funds with no active deal flow in the last 12 months, portfolio companies that have not grown since initial investment, general partners without clear positions on 280E and SAFE Banking Act implications, and platforms that declined to participate in follow-on rounds for existing portfolio companies.

Which Firm Fits Your Needs?

Cannabis tech and SaaS founders building point-of-sale systems, compliance tools, or supply chain software should open conversations with Casa Verde Capital and HALLEY Venture Partners first. Both funds operate strict ancillary-only mandates that eliminate federal banking complications. Their portfolios (Dutchie, Metrc, springbig, Willow Industries) demonstrate the type of scalable software businesses they actively back.

Multi-state operators seeking growth equity to fund expansion across state lines should prioritize Gotham Green Partners (Series A through Series C, public and private co-investment) and Altitude Investment Management (North America and Europe, early-to-growth stage). Both managers deploy the type of growth capital that funds MSO scaling. Gotham Green's reach into publicly traded cannabis companies adds a financing layer that most cannabis-only PE firms cannot offer.

Entourage Effect Capital's seed-stage mandate and 65+ portfolio network make it the best starting point for founders at the earliest stage with $500,000 to $5 million in capital needs. Green Lion Partners serves the equivalent tier in Colorado markets. LPs evaluating cannabis as an asset class should begin with Merida Capital Holdings, which manages five structured funds totaling $200 million with documented exits, and Poseidon Asset Management, one of the longest-tenured active managers in the space.

Founders who need non-equity capital alongside or instead of equity should consider Viridian Capital Advisors, which covers bridge financing, debt facilities, and full-spectrum capital placement advisory. Its transactions carry the institutional credibility of a FINRA/SIPC-registered broker-dealer.

Methodology

This cannabis private equity guide was compiled using industry cannabis fund databases (98 funds tracked as of January 2026), PE deal activity data covering 2021 through Q1 2023, the Viridian Cannabis Deal Tracker, PE industry deal databases, venture databases, New Frontier Data market projections, and cannabis investor directories. Firms were evaluated on disclosed AUM or capital deployed, verifiable portfolio company depth, active investment mandates as of 2025-2026, and stage specialization. Advisory firms were included where executed capital placement activity exceeded $100 million.

Market statistics reflect 2022-2023 figures from industry deal databases. Individual firm profiles reflect publicly available data as of early 2026. This overview does not constitute investment advice. Investors should conduct independent due diligence before engaging with any fund manager referenced herein.